Academic Journal
Latent effector capacity governs reversible T cell exhaustion: A theoretical mathematical model of PD-1 blockade response.
| Τίτλος: | Latent effector capacity governs reversible T cell exhaustion: A theoretical mathematical model of PD-1 blockade response. |
|---|---|
| Συγγραφείς: | Liew AY; Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA., Li Y; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA., Dong H; Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.; Department of Urology, Mayo Clinic, Rochester, MN, USA. |
| Πηγή: | Science advances [Sci Adv] 2026 Oct 16; Vol. 12 (42), pp. eaei0840. Date of Electronic Publication: 2026 Oct 16. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Washington, DC : American Association for the Advancement of Science, [2015]- |
| Ιατρικοί όροι (MeSH): | T-Cell Exhaustion*/drug effects , Immune Checkpoint Inhibitors*/pharmacology , Models, Immunological*, Epigenesis, Genetic ; Humans ; Animals |
| Περίληψη: | T cell exhaustion is often viewed as a terminal state marked by irreversible loss of function during chronic infection and cancer. However, the rapid recovery of antitumor activity in clinical responders after PD-1 blockade suggests that some exhausted T cells retain hidden functional potential. To explain this paradox, we present a theoretical framework that separates latent effector capacity from active effector function. Latent effector capacity represents a history-dependent state reflecting preserved epigenetic accessibility and regulatory readiness, distinct from ongoing gene expression. In this model, PD-1 signaling acts as a reversible mask that suppresses effector function without eliminating the underlying effector capacity. The framework explains preserved chromatin accessibility, rapid reinvigoration after checkpoint blockade, and variable therapeutic responses. By incorporating nonlinear maintenance and erosion of latent effector capacity, the model predicts a bistable system with a point of no return beyond which exhaustion becomes irreversible. These principles may guide development of mechanistically informed biomarkers and artificial intelligence models predicting response to PD-1 therapy. |
| References: | Nat Med. 2022 Jul;28(7):1421-1431. (PMID: 35501486) Sci Immunol. 2023 Aug 4;8(86):eadg0539. (PMID: 37624909) Immunity. 2019 Dec 17;51(6):1043-1058.e4. (PMID: 31810882) Nat Immunol. 2024 Aug;25(8):1344-1354. (PMID: 39025962) Sci Signal. 2023 Nov 28;16(813):eadh2456. (PMID: 38015913) JCI Insight. 2018 Apr 19;3(8):. (PMID: 29669928) Front Immunol. 2025 Dec 04;16:1708873. (PMID: 41425548) Science. 2016 Dec 2;354(6316):1165-1169. (PMID: 27789799) Cancer Immunol Res. 2022 Feb;10(2):154-161. (PMID: 35013002) Nat Immunol. 2022 Jan;23(1):122-134. (PMID: 34937932) Mol Cell. 2020 Mar 5;77(5):937-950.e6. (PMID: 31926851) JCI Insight. 2016 May 5;1(6):. (PMID: 27182556) Annu Rev Immunol. 2019 Apr 26;37:457-495. (PMID: 30676822) Nat Med. 2019 Aug;25(8):1251-1259. (PMID: 31359002) Nat Rev Immunol. 2025 Sep;25(9):662-679. (PMID: 40216888) Annu Rev Immunol. 2008;26:677-704. (PMID: 18173375) Nat Immunol. 2021 Aug;22(8):1020-1029. (PMID: 34312547) Int J Hematol. 2023 May;117(5):634-639. (PMID: 35864292) Cell Rep. 2024 May 28;43(5):114141. (PMID: 38656869) SOJ Immunol. 2017;5(1):1-5. (PMID: 29629436) Sci Signal. 2012 Jun 26;5(230):ra46. (PMID: 22740686) Nat Commun. 2021 Mar 3;12(1):1402. (PMID: 33658501) Cell Rep. 2023 Jun 27;42(6):112649. (PMID: 37330910) Nature. 2026 Jan;649(8095):194-204. (PMID: 41299179) Immunity. 2012 Nov 16;37(5):785-99. (PMID: 23123060) Immunity. 2019 Dec 17;51(6):1028-1042.e4. (PMID: 31810883) Nat Metab. 2020 Oct;2(10):1001-1012. (PMID: 32958939) Annu Rev Immunol. 2024 Jun;42(1):179-206. (PMID: 38166256) Cancer Cell. 2022 Jul 11;40(7):768-786.e7. (PMID: 35750052) Annu Rev Immunol. 2016 May 20;34:539-73. (PMID: 26927206) Annu Rev Immunol. 2025 Apr;43(1):515-543. (PMID: 40279308) Nature. 2019 Jul;571(7764):211-218. (PMID: 31207603) Nat Immunol. 2022 Nov;23(11):1614-1627. (PMID: 36289450) Nat Rev Immunol. 2018 May;18(5):340-356. (PMID: 29379213) Nat Rev Immunol. 2015 Aug;15(8):486-99. (PMID: 26205583) Cancer Immunol Res. 2022 Feb;10(2):162-181. (PMID: 34911739) iScience. 2021 Aug 24;24(9):103020. (PMID: 34522863) Immunity. 2020 May 19;52(5):825-841.e8. (PMID: 32396847) Nature. 2017 May 4;545(7652):60-65. (PMID: 28397821) Nat Immunol. 2022 Nov;23(11):1600-1613. (PMID: 36271148) Nat Commun. 2026 May 23;17(1):. (PMID: 42177167) Nat Rev Immunol. 2019 Nov;19(11):665-674. (PMID: 31570879) Cancer Immunol Res. 2022 Feb;10(2):146-153. (PMID: 34937730) Immunity. 2023 Jun 13;56(6):1320-1340.e10. (PMID: 37315535) Nat Immunol. 2025 Apr;26(4):544-556. (PMID: 40108419) Science. 2016 Dec 2;354(6316):1160-1165. (PMID: 27789795) Nat Rev Immunol. 2022 Apr;22(4):209-223. (PMID: 34253904) Nat Immunol. 2013 Dec;14(12):1212-8. (PMID: 24240160) Nat Med. 2020 Feb;26(2):193-199. (PMID: 32042196) Cancer Immunol Immunother. 2020 Nov;69(11):2165-2167. (PMID: 33011909) FEBS Lett. 2004 Sep 10;574(1-3):37-41. (PMID: 15358536) Sci Adv. 2023 Nov 17;9(46):eadi2414. (PMID: 37967193) |
| Substance Nomenclature: | 0 (Immune Checkpoint Inhibitors) |
| Entry Date(s): | Date Created: 20261016 Date Completed: 20261021 Latest Revision: 20261021 |
| Update Code: | 20261021 |
| PubMed Central ID: | PMC13674514 |
| DOI: | 10.1126/sciadv.aei0840 |
| PMID: | 42886782 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2375-2548 |
|---|---|
| DOI: | 10.1126/sciadv.aei0840 |